
    
      The objective of this study is to prospectively evaluate the performance of Integra Accell
      Evo3 Demineralized Bone Matrix as an adjunct for posterolateral spine fusion with a
      retrospective comparison to a historical patient cohort. The historical patient cohort has
      not been previously published and therefore, no reference to this group can be provided.
    
  